Acumen Pharmaceuticals (ABOS) Times Interest Earned (2021 - 2026)
Acumen Pharmaceuticals recorded quarterly Times Interest Earned of -$19.78 in Q1 2026, up 14.66% quarter-over-quarter from -$23.18 in Q4 2025, and up 33.36% year-over-year from -$14.84 in Q1 2025.
Acumen Pharmaceuticals' Times Interest Earned history runs 5 years deep, the most recent figure standing at -$19.78 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 33.36% year-over-year to -$19.78; the TTM figure through Mar 2026 stood at -$26.84 (up 13.27% YoY), while the FY2025 annual figure was -$29.32, down 4.6% from the prior year.
- Times Interest Earned came in at -$19.78 for Q1 2026 at Acumen Pharmaceuticals, up from -$23.18 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$17.77 in Q1 2024 to a low of -$39.91 in Q2 2025.
- A 4-year average of -$28.09 and a median of -$27.26 in 2025 frame the typical range for Times Interest Earned.
- On a YoY basis, Times Interest Earned climbed as much as 39.29% in 2025 and fell as far as 67.03% in 2025.
- Acumen Pharmaceuticals' Times Interest Earned stood at -$31.82 in 2023, then retreated by 20.01% to -$38.18 in 2024, then soared by 39.29% to -$23.18 in 2025, then gained by 14.66% to -$19.78 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$19.78, -$23.18, and -$24.82 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3.88 |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | -19.78 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.78 |
| Dec 31, 2025 | -23.18 |
| Sep 30, 2025 | -24.82 |
| Jun 30, 2025 | -39.91 |
| Mar 31, 2025 | -29.69 |
| Dec 31, 2024 | -38.18 |
| Sep 30, 2024 | -31.42 |
| Jun 30, 2024 | -24.28 |
| Mar 31, 2024 | -17.77 |
| Dec 31, 2023 | -31.82 |
| Sep 30, 2021 | -171.09 |